European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond

Rezultaty

Recommendations for data reproducibility training

D64 Recommendations for data reproducibility training M36 EUOS

Improved protocols for compound sourcing and acquisition based on EU-OS Ambassador feedback, including a directory of cooperating chemists from each country

D2.1 Improved protocols for compound sourcing and acquisition based on EU-OS Ambassador feedback, including a directory of cooperating chemists from each country (M12) (UH, USC)

Report on implementation of enhanced transfer procedures for data from EU-OS partner sites

D62 Report on implementation of enhanced transfer procedures for data from EUOS partner sites M55 EUOS

Publication describing the performance of the fragment library in screening campaigns

D42 Publication describing the performance of the fragment library in screening campaigns M40 OSI EMBL

Report on scientific publications and dissemination / outreach activities to new communities

D93 Report on scientific publications and dissemination outreach activities to new communities M56 EUOS

Gender action plan

D9.2 Gender action plan (M12) (EU-OS)

Report on outcomes of the chemical optimisation projects

D32 Report on outcomes of the chemical optimisation projects including of gaps in medicinal chemistry services and recommendation for process improvements for EUOS operation M55 EUOS

Mode of action or compound distribution report for compounds from selected projects from phase 1 (responsibility of sites providing access)

D51 Mode of action or compound distribution report for compounds from selected projects from phase 1 responsibility of sites providing access M33 IME

Mode of action or compound distribution report for compounds from selected projects from phase 2 (responsibility of sites providing access)

D52 Mode of action or compound distribution report for compounds from selected projects from phase 2 responsibility of sites providing access M48 IME

Report on the status of co-developed screening technologies

D72 Report on the status of codeveloped screening technologies M56 USC UiO

Report on available courses relevant for users and staff of EU-OS

D8.1 Report on available courses relevant for users and staff of EU-OS (M12) (IMG)

Report on outcomes of the screening projects

D31 Report on outcomes of the screening projects including identification of gaps in screening services and recommendation for process improvements for EUOS operation M35 EUOS

Report on improvements to the access and workflows.

D1.1 Report on improvements to the access and workflows (M12) (EU-OS)

Innovation management plan

D73 Innovation management plan M56 USC UiO

Report on the translation module for EU-OS screening centres

D63 Report on the translation module for EUOS screening centres M55 EUOS

FBDD chemical evolution consultation service guidelines

D4.1 FBDD chemical evolution consultation service guidelines (M12) (OSI, HZI)

Management guidelines

D9.1 Management guidelines (M2) (EU-OS)

Report on engagement measures and successes for extension of EU-OS membership

D13 Report on engagement measures and successes for extension of EUOS membership M55 EUOS

Enhanced Business Plan and financial sustainability model based on EU-OS-DRIVE outcomes

D15 Enhanced Business Plan and financial sustainability model based on EUOSDRIVE outcomes M56 EUOS

Data Management Plan

D6.5 Data Management Plan (M6) (EU-OS)

Final report on the EU-OS academic compound library

D23 Final report on the EUOS academic compound library to include metrics on compound acquisition quality diversity uniqueness etc summaries of training events organized and recommendations for future acquisition campaigns M56 UH USC

Report on report on sustainability aspects and future perspectives for forming major strategic cooperations in the fields of chemical biology and academic drug discovery. Audiences are policy makers and funding bodies

D94 Report on report on sustainability aspects and future perspectives for forming major strategic cooperations in the fields of chemical biology and academic drug discovery Audiences are policy makers and funding bodies M57 EUOS

Report on co-ordination of joined training with other BMS ESFRI projects and establishing new collaborative links

D8.3 Report on co-ordination of joined training with other BMS ESFRI projects and establishing new collaborative links (M18) (IMG)

Report on existing data transfer procedures and gap analysis

D6.1 Report on existing data transfer procedures and gap analysis (M6) (EU-OS)

Report on the evaluation of tools to improve compound registration

D2.2 Report on the evaluation of tools to improve compound registration (M18) (UH, USC)

Roadmap for industry interactions and establishment of industry involvement in EU-OS’s activities

D7.1 Roadmap for industry interactions and establishment of industry involvement in EU-OS’s activities (M8) (USC, UiO)

Report on newly developed courses organized by EU-OS-DRIVE

D8.2 Report on newly developed courses organized by EU-OS-DRIVE (M18) (IMG)

Handbook and defined user workflows for two new categories of partner sites

D12 Handbook and defined user workflows for two new categories of partner sites M46 EUOS

Delivery of periodic, mid-term and final reports

D9.5 Delivery of periodic, mid-term and final reports (M12, 24, 36, 48) (EU-OS) due M12, M24, M36, M48

Socio-economic impact study and documented refined KPIs

D1.4 Socio-economic impact study and documented refined KPIs (M56) (EU-OS)

Open Research Data Pilot

Note The Assay Providing User may request an optional grace period which allows for an indepth characterisation of the identified compounds and facilitates the publication of research findings in highlevel peerreviewed journals or the application for a patent If an IP position is being sought then a grace period of up to 24 month with the possibility to extend to 36 months in exceptional circumstances may be granted These grace periods align with current practice of other initiatives eg the IMI European Lead Factory which plans to release the Qualifiedhitlists of their projects after a defined grace period

Publikacje

Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking

Autorzy: Schuller, Marion Correy, Galen J. Gahbauer, Stefan Fearon, Daren Wu, Taiasean Díaz, Roberto Efraín Young, Iris D. Martins, Luan Carvalho Smith, Dominique H. Schulze-Gahmen, Ursula Owens, Tristan W. Deshpande, Ishan Merz, Gregory E. Thwin, Aye C. Biel, Justin T. Peters, Jessica K. Moritz, Michelle Herrera, Nadia Kratochvil, Huong T. Aimon, Anthony Bennett, James M. Neto, Jose Brandao Cohen, Aina
Opublikowane w: Science Advances, Numer Vol 7, Numer 16, 2021, Strona(/y) eabf8711, ISSN 2375-2548
Wydawca: American Association for the Advancement of Science
DOI: 10.1126/sciadv.abf8711

HTSDSF Explorer, A Novel Tool to Analyze High-throughput DSF Screenings

Autorzy: Pau Martin-Malpartida, Emil Hausvik, Jarl Underhaug, CarlesTorner, AuroraMartinez, Maria J.Macias
Opublikowane w: JMB Journal of Molecular Biology, Numer Volume 434, Numer 11, 15 June 2022, 167372, 2022, ISSN 0022-2836
Wydawca: Academic Press
DOI: 10.1016/j.jmb.2021.167372

Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery

Autorzy: Alessandra Silvestri, Francisca Vicente, María J.Vicent, Bahne Stechmann, Wolfgang Fecke
Opublikowane w: Drug Discovery Today, Numer Volume 26, Numer 6, June 2021, 2021, Strona(/y) Pages 1369-1381, ISSN 1359-6446
Wydawca: Elsevier BV
DOI: 10.1016/j.drudis.2021.02.024

MBC and ECBL libraries: outstanding tools for drug discovery

Autorzy: Tiziana Ginex; Enrique Madruga; Ana Martinez; Carmen Gil
Opublikowane w: Frontiers in Pharmacology, Numer Volume 14 - 2023, 2023, ISSN 1663-9812
Wydawca: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1244317

A Rapid, Convergent Approach to the Identification of Exosome Inhibitors in Breast Cancer Models

Autorzy: Zoraida Andreu; Esther Masiá; David Charbonnier; María J. Vicent
Opublikowane w: Nanotheranostics, Numer 2023 Jan 1;7(1):1-21., 2023, ISSN 2206-7418
Wydawca: Ivyspring International Publisher
DOI: 10.7150/ntno.73606

Development and Characterization of a FKBP51FK1 Affinity Matrix for Protein-Protein Interaction Studies

Autorzy: Stephanie Merz
Opublikowane w: 2022
Wydawca: TU Darmstadt, Germany

Wyszukiwanie danych OpenAIRE...

Podczas wyszukiwania danych OpenAIRE wystąpił błąd

Brak wyników